Skip to main content

U.S. Supreme Court declines to hear biologic drug patent fight

WASHINGTON, Dec 12 (Reuters) - The U.S. Supreme Court on Monday declined to hear a case over whether companies that make copycat versions of biologic drugs must wait 180 days after winning federal approval before bringing them to the market.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.